Home › Activist investors › Two Seas Capital LP
Campaign activist. Positions and campaigns from Two Seas Capital LP’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| USA TODAY Co., Inc. | 9.81%14,504,707 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 2, 2026 | Feb 18, 2025 | Increased Oct 6, 2026 | ▲ 0.23 pts | Increased | 13F: none stated |
| Nektar Therapeutics | 9.80%3,345,978 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 7, 2026 | Feb 11, 2026 | Increased Oct 6, 2026 | ▲ 0.74 pts | Increased | 13F: none stated |
| Sable Offshore Corp. | 8.91%17,101,876 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 7, 2026 | Feb 18, 2025 | Increased Oct 6, 2026 | ▲ 4.55 pts | Increased | 13F: none stated |
| Calumet, Inc. | 6.07%5,280,659 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Mar 31, 2026 | Nov 14, 2024 | Decreased Oct 6, 2026 | ▼ 1.54 pts | Decreased | 13F: none stated |
| Arbutus Biopharma Corporation | 4.12%8,143,994 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 10, 2026 | Feb 14, 2022 | Decreased Oct 6, 2026 | ▼ 5.54 pts | Decreased | 13F: none stated |
| Quantum Corp. | 3.78%1,490,992 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 6, 2026 | Aug 12, 2026 | Decreased Oct 6, 2026 | ▼ 2.54 pts | Decreased | 13F: none stated |
| Core Scientific, Inc. | 3.64%11,739,574 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 2, 2026 | May 15, 2024 | Increased Oct 6, 2026 | ▲ 0.74 pts | Increased | 13F: none stated |
| STAAR Surgical Company | 2.60%1,304,957 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Oct 30, 2026 | May 15, 2026 | Increased Oct 6, 2026 | ▲ 0.48 pts | Increased | 13F: none stated |
| Immunovant Inc. | 2.23%4,612,692 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 3, 2026 | Nov 14, 2023 | Increased Oct 6, 2026 | ▲ 0.71 pts | Increased | 13F: none stated |
| Sotera Health Company | 2.14%6,111,053 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Oct 27, 2026 | May 15, 2024 | Increased Oct 6, 2026 | ▲ 0.09 pts | Increased | 13F: none stated |
| uniQure N.V. | 1.89%1,324,022 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 2, 2026 | May 15, 2026 | Decreased Oct 6, 2026 | ▼ 0.19 pts | Decreased | 13F: none stated |
| Talen Energy Corporation | 1.23%535,493 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Nov 3, 2026 | Aug 14, 2024 | Increased Oct 6, 2026 | ▲ 0.17 pts | Increased | 13F: none stated |
| Roivant Sciences Ltd. | 1.01%7,325,356 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Jul 31, 2026 | Feb 14, 2022 | Decreased Oct 6, 2026 | ▼ 0.16 pts | Decreased | 13F: none stated |
| Odyssey Marine Exploration Inc | 10.0%5,857,448 shares | Schedule 13D, filed Apr 13, 2026 | Apr 13, 2026 | — | — | — | Seeks changes or engagement |
| Core Scientific, Inc. | 6.3%19,122,842 shares | Schedule 13D, filed Aug 8, 2025 | Aug 8, 2025 | — | — | — | Seeks changes or engagement |
| Pavmed Inc. | 5.77%461,539 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 13, 2026 | May 15, 2026 | — | 0.00 pts | — | 13F: none stated |
| Lucid Diagnostics Inc. | 2.95%6,000,000 shares | 13F, quarter ended Sep 30, 2026filed Oct 6, 2026; % of shares outstanding as of Aug 10, 2026 | Nov 14, 2025 | — | 0.00 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“…securities because they believed that such securities, when purchased, represented an attractive investment opportunity. On April 8, 2026, the Issuer, Oceanus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer ("Merger Sub"), and American Ocean Minerals Corporation, a Delaware corporation ("AOM,") entered into an Agreement and Plan of Merger (the "Merger Agreement") pursuant to which Merger Sub will merge with and into AOM,…”
“…purchased, represented an attractive investment opportunity. On July 7, 2025, the Issuer, CoreWeave, Inc., a Delaware corporation ("CoreWeave"), and Miami Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of CoreWeave ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides, upon the terms and subject to the conditions set forth therein, for a merger between Merger Sub…”
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Core Scientific, Inc.Board seatsGovernance changes | Stake reported below 5% | Apr 23, 2026 | Aug 7, 2025 | Proxy contest filed | latest (26) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Indivior PLC | 5.0% | Schedule 13D/A, filed Dec 23, 2025 | Reported below 5% in a 13D/A | Dec 23, 2025 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Core Scientific, Inc. | Settlement | agreement with the company | Feb 19, 2026 | Aug 7, 2025 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 3 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“Two Seas agreed to customary standstill provisions, effective for a one-year period following the execution of the Cooperation Agreement, and voting commitments, effective until the 2027 Annual Meeting.” 8-K, Feb 19, 2026
“Two Seas agreed to customary standstill provisions, effective for a one-year period following the execution of the Cooperation Agreement, and voting commitments, effective until the 2027 Annual Meeting.” 8-K, Feb 18, 2026
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Two Seas Capital LP’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Aklog Lishan | Schedule 13D | Apr 9, 2026 | 5.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Madison Avenue International LP | Schedule 13G | Apr 20, 2026 | 5.8% |
| BlackRock, Inc. | Schedule 13G | Apr 24, 2026 | 13.1% |
| Point72 Asset Management, L.P. | Schedule 13G | May 12, 2026 | 5.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| The Vanguard Group | Schedule 13G | Jan 30, 2026 | 5.0% |
| G1 Execution Services, LLC | Schedule 13G | Feb 13, 2026 | 4.0% |
| FMR LLC | Schedule 13G | Mar 6, 2026 | 11.1% |
| Two Seas Capital LP | Schedule 13G | Apr 17, 2026 | 6.8% |
| BVF Partners L P/Il | Schedule 13G | May 15, 2026 | 9.8% |
| BlackRock, Inc. | Schedule 13G | Jul 29, 2026 | 7.8% |
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Heritage Group | Schedule 13D | Jul 11, 2024 | 17.2% |
| Wasserstein Debt Opportunities Management, L.P. | Schedule 13D | Feb 25, 2025 | 7.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Rubric Capital | 13F | Nov 13, 2024 | 8.3% |
| Sachem Head | 13F | Nov 14, 2024 | 2.7% |
| Carronade Capital | 13F | Nov 14, 2024 | 1.5% |
| The Vanguard Group | Schedule 13G | Jan 8, 2025 | 10.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| BlackRock Inc. | Schedule 13D | Nov 27, 2023 | 1.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Sachem Head | 13F | May 15, 2024 | 5.5% |